Home > Result Summaries: Compounds > Combined Measles, Mumps, Rubella, Varicella Vaccine Result Summaries: Combined Measles, Mumps, Rubella, Varicella Vaccine GSKStudy ID Phase Title Summary (Download) 103388 Phase 3 Blinded, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella candidate vaccine given to healthy children during the second year of life (0 citation(s)) 104020 phase 4 Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life (0 citation(s)) 104389 phase 3 Blinded, randomised, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella candidate vaccine given to healthy children in their second year of life (4 citation(s)) 105908 Phase 2 Comparative study evaluating the immunogenicity and safety of MeMuRu-OKA vaccine and measles-mumps-rubella vaccine (Priorix™) co-administered with varicella vaccine (Varilrix™) in children primed with measles-mumps-rubella vaccine (1 citation(s)) 105909 Phase 2 Comparative study evaluating the immunogenicity & safety of MeMuRu-OKA vaccine & measles-mumps-rubella vaccine (Priorix™) co-adm. with varicella vaccine (Varilrix™) in children primed with both measles-mumps-rubella & varicella vaccines (1 citation(s)) 106670 Phase 3 Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus alternative administration route of combined MeMuRu-OKA vaccine to healthy children aged 11 to 21 months. (1 citation(s)) 108760 phase 2 Immunogenicity & safety study of GSK Biologicals’ 208136 vaccine formulated with new measles and rubella working seeds (0 citation(s)) 109995 phase 3 Non-inferiority of GSK Biologicals’ measles-mumps-rubella-varicella (MMRV) vaccine 208136 vs Priorix™ and Priorix™ coadministered with Varilrix™ (comparator) and to evaluate non-inferiority of Priorix™ and MMRV vaccine 208136 vs comparator (0 citation(s)) 110058 phase 2 Immunogenicity of GlaxoSmithKline Biologicals' MMRV vaccine (208136) vs. ProQuad®, when coadministered with hepatitis A and pneumococcal conjugate vaccines to children 12-14 months of age. (1 citation(s)) 110876 phase 3 Immunogenicity & safety study of GSK Biologicals’ combined measles-mumps-rubella-varicella vaccine 208136 (0 citation(s)) 208136/006 Phase 2 Study evaluating in healthy children safety and immunogenicity of GSK Bios' combined Measles-Mumps-Rubella-Varicella vaccine, compared to GSK Bios' Varicella and Measles-Mumps-Rubella vaccines admind as separate injections (3 citation(s)) 208136/007 Phase 3 Study to assess consistency of 3 production lots of GSK Bios’ combined measles-mumps-rubella-varicella vaccine in terms of immunogenicity and safety, compared to administration of GSK Bios’ measles-mumps-rubella vaccine and varicella vaccine in healthy children in their second year of life (0 citation(s)) 208136/013 Phase 3 Study to assess immunogenicity and safety of one dose of GSK Bios’ live attenuated MMRV vaccine, co-admind with a booster dose of the GSK Bios’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b conjugate vaccine (3 citation(s)) 208136/014 Phase 3 Study to evaluate immunogenicity and safety of one dose of GSK Bios’ combined measles-mumps-rubella-varicella vaccine given to healthy children previously primed with one dose of measles-mumps-rubella vaccine in their second year of life and presumed seronegative for varicella (0 citation(s)) 208136/016 Phase 3 Study to assess immunogenicity and safety of two lots of GSK Bios’ live attenuated measles-mumps-rubella-varicella vaccine, at two different titres, given as a single injection to healthy children with GSK Bios’ measles-mumps-rubella vaccine as control group (0 citation(s)) 208136/017 Phase 2 Study to assess immunogenicity, reactogenicity and safety of a 2nd dose of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine given in healthy children of 5 to 6 years of age (3 citation(s)) 208136/018 Phase 3 Study to evaluate immunogenicity and safety of GSK Bios’ MeMuRu-OKA vaccine compared to concomitant administrations of GSK Bios’ Priorix™ and Varilrix™ vaccines (5 citation(s)) 208136/019 Phase 3 Study to evaluate immunogenicity and safety of one dose of GSK Bios’ measles-mumps-rubella-varicella vaccine given to healthy children previously primed with one dose of measles-mumps-rubella vaccine (1 citation(s)) 208136/022 Phase 3 Study to evaluate immunogenicity and safety of one dose of GSK Bios’ combined measles-mumps-rubella-varicella vaccine compared to concomitant administrations of GSK Bios’ measles-mumps-rubella vaccine and varicella vaccine (0 citation(s)) 208136/038 Phase 3 Study to evaluate immunogenicity and safety of three production lots of GSK Bios’ combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Bios' Priorix™ and Varilrix™ vaccines (4 citation(s)) 208136/040 phase 3 Study to evaluate immunogenicity and safety of three production lots of GSK Bios’ combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Bios’ Priorix® and Varilrix® vaccines (3 citation(s)) 208136/041 phase 3 Study to evaluate immunogenicity and safety of three production lots of GSK Bios’ combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Bios’ Priorix® and Varilrix® vaccines. (2 citation(s)) MMRV (208136) - Meta-analysis n\a Integrated Summary Output (ISO) on febrile convulsions (0 citation(s))
